The respiratory syncytial virus (RSV) vaccine manufactured by Moderna, Inc. received approval last week by the Food and Drug Administration to prevent lower respiratory tract disease caused by RSV in individuals 18-59 years of age who are at increased risk for disease. The vaccine was previously approved in May 2024 for adults aged 60 years and older, according to a press release, and this new approval expands the age range for use to a younger …
Read More